Trimethoprim–Sulfamethoxazole and Olmesartan/Amlodipine/Hydrochlorothiazide
Trimethoprim–sulfamethoxazole (TMP–SMX) can precipitate clinically significant hyperkalemia and acute kidney injury in patients receiving renin–angiotensin system (RAS) blockade with an ARB. [1]
The olmesartan/amlodipine/hydrochlorothiazide fixed-dose combination provides ARB-mediated RAS inhibition via olmesartan and thiazide diuretic exposure via hydrochlorothiazide. [2]
Interaction Mechanism: Hyperkalemia Risk
Trimethoprim can cause hyperkalemia by reducing potassium secretion in the distal nephron. [1]
Hyperkalemia risk increases when TMP–SMX is coadministered with agents that also increase serum potassium via RAS blockade (including ACE inhibitors), with reported cases in the literature. [1]
Olmesartan is an ARB, which is a RAS inhibitor associated with hyperkalemia risk through suppression of aldosterone-mediated potassium excretion. [2]
Interaction Mechanism: Renal Function Deterioration
Trimethoprim–SMX exposure may worsen renal function in patients with underlying renal insufficiency or when nephrotoxic or renal perfusion–altering physiology is present. [1]
Olmesartan/amlodipine/hydrochlorothiazide labeling includes the need to closely monitor renal function and electrolytes in patients receiving agents that affect the RAS. [2]
Clinical Consequences to Monitor
Hyperkalemia can be clinically serious and has been associated with sudden death risk in observational evidence among patients receiving ACE inhibitors or ARBs treated with co-trimoxazole. [3]
Creatinine and blood urea nitrogen may rise with RAS blockade and can worsen in the setting of concomitant therapy that stresses renal function. [2]
Hypotension or volume depletion can contribute to renal vulnerability in patients receiving the combination product and TMP–SMX, particularly in older or volume-depleted states. [2]
Drug–Drug Interaction Product-Specific Assessment
Olmesartan (ARB component)
TMP–SMX (trimethoprim component) increases the risk of hyperkalemia when coadministered with RAS inhibitors, including ACE inhibitors per case reports. [1]
Olmesartan/amlodipine/hydrochlorothiazide is a dual RAS-inhibiting regimen only by virtue of ARB activity from olmesartan, which contributes to hyperkalemia risk during coadministration with TMP–SMX. [2]
Hydrochlorothiazide (thiazide component)
Hydrochlorothiazide can lower serum potassium, which may partially counterbalance TMP–SMX–induced hyperkalemia. [2]
Hydrochlorothiazide does not eliminate TMP–SMX–associated hyperkalemia risk, especially with concomitant ARB therapy and impaired renal function. [1]
Amlodipine (calcium channel blocker component)
No specific pharmacokinetic interaction between TMP–SMX and amlodipine is described in the olmesartan/amlodipine/hydrochlorothiazide prescribing information. [2]
Management Implications
Serum potassium and renal function should be monitored during TMP–SMX treatment in patients receiving ARB therapy, particularly in older patients and those with renal insufficiency or other potassium-risk factors. [1]
Concurrent use should be reassessed when monitoring reveals rising serum potassium or worsening renal function. [2]
Common Pitfalls to Avoid
Avoid assuming thiazide-related kaliuresis fully offsets TMP–SMX hyperkalemia risk in patients taking an ARB. [1]
Avoid delayed electrolyte monitoring in patients with renal insufficiency, diabetes, advanced age, or prolonged TMP–SMX exposure. [1]
Avoid treating TMP–SMX–associated hyperkalemia as an isolated laboratory abnormality without urgent clinical and laboratory reassessment, given the demonstrated association with serious outcomes in RAS inhibitor users. [3]
Targets and Thresholds for Laboratory Surveillance
Serum potassium monitoring is warranted when TMP–SMX is coadministered with drugs known to induce hyperkalemia or in patients with renal insufficiency. [1]
Renal function and electrolytes should be closely monitored in patients receiving olmesartan/amlodipine/hydrochlorothiazide along with other agents that affect the RAS. [2]
Summary of Interaction
The clinically important interaction is hyperkalemia and potential worsening of renal function caused by the trimethoprim component of TMP–SMX acting in the setting of ARB-mediated RAS inhibition from olmesartan. [1]
Observational evidence links co-trimoxazole exposure to increased sudden death risk in patients receiving ACE inhibitors or ARBs, consistent with a hyperkalemia-related mechanism. [3]